Share on StockTwits
 

Equities research analysts at UBS AG lifted their EPS estimates on shares of Medivation (NASDAQ:MDVN) in a research note issued to investors on Wednesday, ARN reports. The firm currently has a “buy” rating and a $93.00 price target on the company’s shares. UBS AG’s target price suggests a potential upside of 22.72% from the company’s current price.

In other Medivation news, CEO David Hung sold 150,000 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $73.50, for a total value of $11,025,000.00. Following the completion of the transaction, the chief executive officer now directly owns 950,204 shares in the company, valued at approximately $69,839,994. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of other firms have also recently commented on MDVN. Analysts at Wedbush raised their price target on shares of Medivation to $118.00 in a research note to investors on Wednesday. Separately, analysts at Brean Capital raised their price target on shares of Medivation from $72.00 to $100.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Aegis raised their price target on shares of Medivation from $100.00 to $125.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. Medivation presently has a consensus rating of “Buy” and an average price target of $84.27.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.08. The company had revenue of $108.50 million for the quarter, compared to the consensus estimate of $60.13 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was down 7.4% on a year-over-year basis.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.